AT65474 / Axcynsis Therap - LARVOL DELTA

AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload (AACR 2025) - "The payload, TCS132, is derived from an FDA approved drug and when compared to the parent drug, demonstrates increased potency with broad sub-nanomolar activities across a wide range of cancer cell lines including those resistant to paclitaxel, DM1, MMAE and DXd. Furthermore, safety assessment of AT65474 including GLP-compliant toxicology studies in Cynomolgus monkeys and SD rats reveals a good safety profile of AT65474. Taken together, the results of the nonclinical studies support the intended clinical trial, dose selection, and regimen in humans."

Genito-urinary Cancer • Oncology • Ovarian Cancer • Solid Tumor • Testicular Cancer • CLDN6

Discovery of AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload (AACR 2024) - "In vitro, the payload displays broad sub-nanomolar activity across a wide range of cancer cell lines including those resistant to paclitaxel, DM1, MMAE and DXd. AT65474 was shown to be well tolerated in all xenograft mouse models and a pre-tox study in non-human primates. The combined data support further development of AT65474.​"

Genito-urinary Cancer • Oncology • Ovarian Cancer • Solid Tumor • Testicular Cancer • CLDN6